欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
SE/H/0171/001
药品名称
Hemosol B0
活性成分
[No Active-Substance specified] 0.0 -
剂型
Solution for haemodialysis/haemofiltration
上市许可持有人
Baxter Holding B.V. Netherlands
参考成员国 - 产品名称
Sweden (SE)
互认成员国 - 产品名称
Cyprus (CY)
HEMOSOL B0 SOLUTION FOR HAEMOFILTRATION
Slovakia (SK)
Hemosol BO
Belgium (BE)
United Kingdom (Northern Ireland) (XI)
Hemosol B0
Netherlands (NL)
Croatia (HR)
Portugal (PT)
Greece (GR)
Spain (ES)
France (FR)
Hemosol
Austria (AT)
Hemosol BO Lösung für Hämofiltration und Hämodialyse
Denmark (DK)
Czechia (CZ)
Hemosol B0
Estonia (EE)
HEMOSOL B0
Lithuania (LT)
Hemososl B0 hemodializės/hemofiltracijos tirpalas
Latvia (LV)
Hemosol B0 šķīdums hemofiltrācijai un hemodialīzei
Poland (PL)
Norway (NO)
Iceland (IS)
Luxembourg (LU)
Bulgaria (BG)
Hemosol
Finland (FI)
Hemosol B0
Ireland (IE)
Germany (DE)
Hemosol B0
Malta (MT)
Slovenia (SI)
许可日期
1999/05/04
最近更新日期
2024/03/01
药物ATC编码
B05ZB Hemofiltrates
申请类型
TypeLevel1:
Known Active Substance
TypeLevel2:
Initial Application
TypeLevel3:
Bibliographic Article 4.8 (a) (ii)
TypeLevel4:
Chemical Substance
TypeLevel5:
Prescription Only
附件文件下载
Final PL
|
common-pl-2016-11-hospasol145
Date of last change:2017/03/24
Final PL
|
common-pl-2016-11-biphozyl
Date of last change:2017/03/24
Final PL
|
common-pl-2016-11-hemosol
Date of last change:2017/03/24
Final PL
|
common-pl-2016-11-hospasol167
Date of last change:2017/03/24
Final PL
|
common-pl-2016-11-phoxilium
Date of last change:2017/03/24
Final PL
|
common-pl-2016-11-regiocit
Date of last change:2017/03/24
Final SPC
|
SE/H/0171/001_Final SPC
Date of last change:2014/01/15
PAR
|
SE/H/0171/001_PAR
Date of last change:2014/01/15
市场状态
Positive
©2006-2024
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase